In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Cagri Peptide Research Amylin Analog RUO USA Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Nature Communications Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet